CEA and CA19.9 as Early Predictors of Progression in Advanced/Metastatic Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy and Bevacizumab

By Petrioli Roberto   Licchetta Antonella   Roviello Giandomenico   Pascucci Alessandra   Francini Edoardo   Bargagli Gianluca   Conca Raffaele   Miano Salvatora Tindara   Marzocca Giuseppe   Francini Guido    

Cancer Investigation, Vol. 30, Iss. 1, 2012-01 ,pp. : 65-71

Informa Healthcare

Access to resources Recommend Favorite

Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer

By Sørbye Halfdan   Berglund Åke   Tveit Kjell Magne   Øgreid Dagfinn   Wanderås Eva Hoff   Wentzel-Larsen Tore   Dahl Olav   Glimelius Bengt  

Acta Oncologica, Vol. 46, Iss. 7, 2007-01 ,pp. : 982-988

Informa Healthcare

Access to resources Recommend Favorite

Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer

By Argyriou Andreas   Polychronopoulos Panagiotis   Iconomou Gregoris   Koutras Angelos   Makatsoris Thomas   Gerolymos Miltiadis   Gourzis Philippos   Assimakopoulos Konstantinos   Kalofonos Haralabos   Chroni Elisabeth  

Acta Oncologica, Vol. 46, Iss. 8, 2007-01 ,pp. : 1131-1137

Informa Healthcare

Access to resources Recommend Favorite

Oxaliplatin-based chemotherapy induces extravasated platelet aggregation in the liver

By                                      

Molecular and Clinical Oncology, Vol. 3, Iss. 3, 2015-01 ,pp. : 555-558

Science Publishers

Access to resources Recommend Favorite

Pathological complete response of colorectal liver metastases following chemotherapy with S-1 and oxaliplatin (SOX) in combination with bevacizumab: A case report

By                      

Oncology Letters, Vol. 2, Iss. 2, 2011-01 ,pp. : 201-205

Spandidos Publications

Access to resources Recommend Favorite